Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome

Therapeutic Advances in Musculoskeletal Disease

Volumn 7, Issue 1, 2015, Pages 26-30

  Rodríguez Pintó, Ignasi ^a   Cervera, Ricard ^a   Espinosa, Gerard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

anti CD20; catastrophic antiphospholipid syndrome; refractory; rituximab

Indexed keywords

ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANCA ASSOCIATED VASCULITIS; ANTIPHOSPHOLIPID SYNDROME; COGNITIVE DEFECT; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG MEGADOSE; HUMAN; IMMUNOLOGICAL MEMORY; KIDNEY DISEASE; LARGE CELL LYMPHOMA; LUPUS ERYTHEMATOSUS NEPHRITIS; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SKIN ULCER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84922115374     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X14554793     Document Type: Review

References (22)

1. Asherson R. (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19: 508–512.
2. Asherson R. Cervera R. de Groot P. Erkan D. Boffa M. Piette J. et al. (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12: 530–534.
3. Berman H. Rodríguez-Pintó I. Cervera R. Morel N. Costedoat-Chalumeau N. Erkan D. et al. (2013) Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12: 1085–1090.
4. Bucciarelli S. Espinosa G. Cervera R. Erkan D. Gómez-Puerta J. Ramos-Casals M. et al. (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54: 2568–2576.
5. Buch M. Smolen J. Betteridge N. Breedveld F. Burmester G. Dörner T. et al. (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70: 909–920.
6. Cambridge G. Isenberg D. Edwards J. Leandro M. Migone T. Teodorescu M. et al. (2008) B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 67: 1011–1016.
7. Cervera R. Bucciarelli S. Plasín M. Gómez-Puerta J. Plaza J. Pons-Estel G. et al. (2009) Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the ‘CAPS Registry’. J Autoimmun 32: 240–245.
8. Duxbury B. Combescure C. Chizzolini C. (2013) Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 22: 1489–1503.
9. Erkan D. Espinosa G. Cervera R. (2010) Catastrophic antiphospholipid syndrome. Updated diagnostic algorithms. Autoimmun Rev 10: 74–79.
10. Erkan D. Vega J. Ramon G. Kozora E. Lockshin M. (2013) A pilot open label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 65: 464–471.
11. Erre G. Pardini S. Faedda R. Passiu G. (2008) Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 17: 50–55.
12. Espinosa G. Cervera R. Asherson R. (2007) Catastrophic antiphospholipid syndrome and sepsis. A common link? J Rheumatol 34: 923–926.
13. Faillace C. de Carvalho J. (2012) Antiphospholipid syndrome development after rituximab treatment. Joint Bone Spine 79: 200–201.
14. Golay J. Zaffaroni L. Vaccari T. Lazzari M. Borleri G. Bernascoli S. et al. (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD 55 and CD 59 regulate complement-mediated cell lysis. Blood 95: 3900–3908.
15. Ioannou Y. Lambrianides A. Cambridge G. Leandro M. Edwards J. Isenberg DA. (2008) B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis 67: 425–426.
16. Jones R. Cohen Tervaert J. Hauser T. Luqmani R. Morgan M. Peh C. et al. (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211–220.
17. Merrill J. Neuwelt C. Wallace D. Shanahan J. Latinis K. Oates J. et al. (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62: 222–233.
18. Mosca M. van Vollenhoven R. (2013) New drugs in systemic lupus erythematosus: when to start and when to stop. Clin Exp Rheumatol 31(4 Suppl. 78): S82–S85.
19. Rovin B. Furie R. Latinis K. Looeny R. Fervenza F. Sanchez-Guerrero J. et al. (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. The lupus nephritis assessment with rituximab study. Arthritis Rheum 64: 1215–1226.
20. Silverman G. Weisman S. (2003) Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48: 1484–1492.
21. Stone J. Merkel P. Spiera R. Seo P. Langford C. Hoffman G. et al. (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221–232.
22. Youinou P. Renaudineau Y. (2004) The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb Res 114: 363–369.